These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 23765245)

  • 1. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice.
    Buza N; English DP; Santin AD; Hui P
    Mod Pathol; 2013 Dec; 26(12):1605-12. PubMed ID: 23765245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of HER2 protein overexpression and HER2 gene amplification in endometrial clear cell carcinoma.
    Sukov WR; Zhou J; Geiersbach KB; Keeney GL; Carter JM; Schoolmeester JK
    Hum Pathol; 2023 Jul; 137():94-101. PubMed ID: 37094656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand.
    Buza N
    Arch Pathol Lab Med; 2021 Jun; 145(6):687-691. PubMed ID: 32649220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma.
    Buza N; Hui P
    Arch Pathol Lab Med; 2022 Jun; 146(5):0. PubMed ID: 35687792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study.
    Buza N; Euscher ED; Matias-Guiu X; McHenry A; Oliva E; Ordulu Z; Parra-Herran C; Rottmann D; Turner BM; Wong S; Hui P
    Mod Pathol; 2021 Jun; 34(6):1194-1202. PubMed ID: 33536574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas.
    Mentrikoski MJ; Stoler MH
    Am J Surg Pathol; 2014 Jun; 38(6):844-51. PubMed ID: 24698965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting.
    Buza N
    Int J Gynecol Pathol; 2021 Jan; 40(1):17-23. PubMed ID: 33290351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy.
    Rottmann D; Snir OL; Wu X; Wong S; Hui P; Santin AD; Buza N
    Mod Pathol; 2020 Jan; 33(1):118-127. PubMed ID: 31477811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 IHC Expression and Gene Amplification in p53-aberrant High-grade Endometrial Endometrioid Carcinoma Suggests That This Population May Benefit From HER2 Testing and Targeted Therapy.
    Joehlin-Price AS; Komforti MK; Ladwig NR; Devine P; Hoyle C; McCoy L; Sprague C; Astbury C; Hoda R; Chen YY; Garg K
    Am J Surg Pathol; 2023 May; 47(5):580-588. PubMed ID: 36939053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma.
    Buza N; Hui P
    Genes Chromosomes Cancer; 2013 Dec; 52(12):1178-86. PubMed ID: 24123408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity.
    Rottmann D; Assem H; Matsumoto N; Wong S; Hui P; Buza N
    Int J Gynecol Pathol; 2021 May; 40(3):263-271. PubMed ID: 32897955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 in uterine serous carcinoma: Current state and clinical perspectives.
    Navarro Sanchez JM; Finkelman BS; Turner BM; Katerji H; Wang X; Varghese S; Wang T; Peng Y; Hicks DG; Zhang H
    Am J Clin Pathol; 2023 Oct; 160(4):341-351. PubMed ID: 37267036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility.
    Moktefi A; Pouessel D; Liu J; Sirab N; Maille P; Soyeux P; Bergman CC; Auriault ML; Vordos D; Taille A; Culine S; Allory Y
    Mod Pathol; 2018 Aug; 31(8):1270-1281. PubMed ID: 29467478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays.
    Robinson CL; Harrison BT; Ligon AH; Dong F; Maffeis V; Matulonis U; Nucci MR; Kolin DL
    Mod Pathol; 2021 Mar; 34(3):603-612. PubMed ID: 33077919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of HER2 DAKO HercepTest and Ventana 4B5 immunohistochemical assays on detecting HER2 gene-amplification in uterine serous carcinomas.
    Navarro Sanchez JM; Finkelman BS; Tyburski H; Turner BM; Moisini I; Katerji H; Varghese S; Wang X; Schiffhauer LM; Chen JJ; Hicks DG; Zhang H
    Hum Pathol; 2024 Jun; 148():51-59. PubMed ID: 38740270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2 overexpression in female genital tract clear cell carcinomas: Evaluation of different scoring guidelines, clinicopathological features and prognostic impact.
    Edjtemaei R; Nili F; Jahanzad I; Ameli F; Ghasemi D
    Ann Diagn Pathol; 2023 Oct; 66():152184. PubMed ID: 37543027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Prognostic Effect of
    Bozkurt KK; Çiriş İM; Başpınar Ş; Çetin B; Erdemoğlu E; Bircan S; Ertunç O
    Int J Surg Pathol; 2023 Jun; 31(4):365-374. PubMed ID: 35611517
    [No Abstract]   [Full Text] [Related]  

  • 18. HER2 Protein Overexpression and Gene Amplification in Tubo-Ovarian High-grade Serous Carcinomas.
    Ersoy E; Cao QJ; Otis CN
    Int J Gynecol Pathol; 2022 Jul; 41(4):313-319. PubMed ID: 34320531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2/ ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors.
    Smithgall MC; Yemelyanova A; Mathew S; Gogineni S; He B; Zhang T; Robinson BD; Tu JJ
    Int J Gynecol Pathol; 2024 Mar; 43(2):134-139. PubMed ID: 37406458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
    Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
    Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.